Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/41535
DC FieldValueLanguage
dc.contributor.authorRodríguez-González, Faynaen_US
dc.contributor.authorMartínez-Quintana, Efrenen_US
dc.contributor.authorSaavedra Santana, Pedroen_US
dc.contributor.authorMedina-Gil, José M.en_US
dc.contributor.authorRiaño, Martaen_US
dc.contributor.authorGaray Sanchez, Palomaen_US
dc.contributor.authorTugores, Antonioen_US
dc.date.accessioned2018-07-11T12:04:55Z-
dc.date.available2018-07-11T12:04:55Z-
dc.date.issued2018en_US
dc.identifier.issn0091-2700en_US
dc.identifier.urihttp://hdl.handle.net/10553/41535-
dc.description.abstractAlong with aspirin, clopidogrel has been a widely used antiplatelet therapeutic regimen. Although generally well tolerated, its efficacy varies among individuals, with the main hypothesis that its bioavailability relies on its bioconversion to the active compound, which, in turn, depends on the genetic background and/or interactions with other drugs. To determine which factors influenced response in our patients, 368 patients receiving combined antiaggregation therapy with aspirin and clopidogrel were followed for 1 year to record 30 novel cardiovascular acute events. This clinical relapse was considered a surrogate end point to measure therapeutic response under the influence of the CYP2C19*2, *3, and *17 and CYP3A5*3 alleles, as well as the effects of concomitant medication and the presence of known cardiovascular risk factors and comorbidity. We show that either single CYP2C19 or CYP3A5 genotyping or combined were not useful to predict clinical efficacy in this cohort. Rather than genetic testing, we have found that clinical observations such as suffering type 2 diabetes mellitus requiring insulin, having several vessels affected, and concurrent medication with calcium channel blockers, regardless of CYP3A5 genotype or drug class were, in that order, the strongest independent predictors of disease relapse.en_US
dc.languageengen_US
dc.relation.ispartofJournal of Clinical Pharmacologyen_US
dc.sourceJournal of Clinical Pharmacology[ISSN 0091-2700],v. 58, p. 1274-1283en_US
dc.subject32 Ciencias médicasen_US
dc.subject.otherAspirinen_US
dc.subject.otherClopidogrelen_US
dc.subject.otherCYP2C19en_US
dc.subject.otherCYP3A5en_US
dc.subject.otherDiabetesen_US
dc.subject.otherCalcium channel blockersen_US
dc.titleCYP2C19 or CYP3A5 genotyping does not predict clinical response to clopidogrelen_US
dc.typeinfo:eu-repo/semantics/Articlees
dc.typeArticlees
dc.identifier.doi10.1002/jcph.1144
dc.identifier.scopus85046338601
dc.identifier.isi000443590000005-
dc.contributor.authorscopusid24825586600
dc.contributor.authorscopusid23485891800
dc.contributor.authorscopusid22635626800
dc.contributor.authorscopusid36018832900
dc.contributor.authorscopusid37067926100
dc.contributor.authorscopusid54392283600
dc.contributor.authorscopusid6701671839
dc.description.lastpage1283
dc.description.firstpage1274
dc.relation.volume58
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.contributor.daisngid648988
dc.contributor.daisngid614797
dc.contributor.daisngid247998
dc.contributor.daisngid8720410
dc.contributor.daisngid5257474
dc.contributor.daisngid5981808
dc.contributor.daisngid1234299
dc.contributor.wosstandardWOS:Rodriguez-Gonzalez, F
dc.contributor.wosstandardWOS:Martinez-Quintana, E
dc.contributor.wosstandardWOS:Saavedra, P
dc.contributor.wosstandardWOS:Medina-Gil, JM
dc.contributor.wosstandardWOS:Riano, M
dc.contributor.wosstandardWOS:Garay-Sanchez, P
dc.contributor.wosstandardWOS:Tugores, A
dc.date.coverdateOctubre 2018
dc.identifier.ulpgces
dc.description.sjr0,954
dc.description.jcr2,915
dc.description.sjrqQ2
dc.description.jcrqQ2
dc.description.scieSCIE
item.fulltextSin texto completo-
item.grantfulltextnone-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.deptGIR Estadística-
crisitem.author.deptDepartamento de Matemáticas-
crisitem.author.deptGIR IUIBS: Diabetes y endocrinología aplicada-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.orcid0000-0003-1681-7165-
crisitem.author.orcid0000-0002-1849-9239-
crisitem.author.parentorgDepartamento de Matemáticas-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameMartínez Quintana, Efrén-
crisitem.author.fullNameSaavedra Santana, Pedro-
crisitem.author.fullNameGaray Sanchez, Paloma-
crisitem.author.fullNameTugores Céster,Antonio-
Appears in Collections:Artículos
Show simple item record

SCOPUSTM   
Citations

2
checked on Dec 4, 2022

WEB OF SCIENCETM
Citations

1
checked on Apr 25, 2021

Page view(s)

26
checked on Dec 3, 2022

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.